Management of Carbimazole Dosing with Decreasing T4
Continue carbimazole 30 mg once daily without dose adjustment at this time, and recheck thyroid function (free T4, total T3, and TSH) in 4 weeks. Your T4 has decreased from 40 to 28 pmol/L, showing therapeutic response, but you remain hyperthyroid and have not yet achieved euthyroidism.
Rationale for Continuing Current Dose
Your current carbimazole dose of 30 mg daily is appropriate for your level of hyperthyroidism. The 2018 French guidelines recommend 30 mg daily of thiamazole (equivalent to approximately 45 mg carbimazole) when free T4 is 3-4 times the upper limit of normal 1. Since 10 mg carbimazole converts to approximately 6 mg methimazole/thiamazole 2, your 30 mg carbimazole dose equals roughly 18 mg thiamazole—which is within the recommended range for moderate-to-severe hyperthyroidism.
The decrease from 40 to 28 pmol/L demonstrates that the medication is working, but you have not reached the euthyroid target yet (normal free T4 is typically 10-26 pmol/L). Premature dose reduction at this stage would risk inadequate control of your hyperthyroidism.
Monitoring Strategy
According to American Thyroid Association guidelines, biochemical monitoring should continue at 4-6 week intervals while you remain thyrotoxic 2. At your next assessment:
- Measure free T4, total T3, and TSH (TSH may remain suppressed for a month or longer even after thyroid hormones normalize, so interpret cautiously) 2
- Assess clinical symptoms: weight, pulse rate, tremor, heat intolerance
- Check for adverse effects: Ask about fever, sore throat, rash, jaundice, joint pain, or abdominal symptoms 2
When to Adjust Dosage
Reduce carbimazole dose only when:
- Free T4 enters the normal range (typically 10-26 pmol/L)
- You become clinically euthyroid
- This usually occurs within 1-3 months of starting therapy 3
The goal is to titrate down to a maintenance dose of 5-15 mg carbimazole daily once euthyroidism is achieved 2. The 2018 guidelines emphasize using the "adapted dose" protocol—adjusting to the minimum dose needed to maintain euthyroid status 1.
Important Caveats
Risk of Overtreatment
Studies show that higher initial doses (40 mg carbimazole) carry greater risk of iatrogenic hypothyroidism compared to 20 mg daily 4. However, your current 30 mg dose is intermediate and appropriate given your T4 level remains elevated. The key is not to continue high doses once euthyroidism is achieved.
Monitoring for Agranulocytosis
While rare (occurring in approximately 0.1-0.5% of patients), agranulocytosis is a potentially life-threatening complication that typically occurs within the first 3 months of therapy 5. You should:
- Stop carbimazole immediately and contact your physician if you develop fever, sore throat, mouth ulcers, or signs of infection 2, 6
- Obtain a white blood cell count with differential during any febrile illness 2
Expected Timeline
Most patients achieve euthyroidism within 4-8 weeks with adequate dosing 2. Research shows that 40% of patients with severely elevated T4 (>90 pmol/L) achieve euthyroid status by 4 weeks on 30 mg thiamazole, compared to only 15% on lower doses 1. Your response trajectory appears appropriate.
Treatment Duration
Once euthyroid, continue antithyroid drug therapy for 12-18 months total before considering discontinuation 1. Stopping too early significantly increases relapse risk.
Do not reduce your carbimazole dose yet—your thyroid function is improving but not yet normalized. Recheck in 4 weeks and adjust only when free T4 enters the normal range.